PGNY Quote, Financials, Valuation and Earnings

Clover Health Investments Corp. has a net margin of 4.43% compared to Progyny, Inc.'s net margin of -4.91%. Progyny, Inc.'s return on equity of 11.79% beat Clover Health Investments Corp.'s return on equity of -16.93%.

Progyny, Inc. has a consensus price target of $30.91, signalling upside risk potential of 29.49%. On the other hand Clover Health Investments Corp. has an analysts' consensus of $3.23 which suggests that it could grow by 44.35%. Given that Clover Health Investments Corp. has higher upside potential than Progyny, Inc., analysts believe Clover Health Investments Corp. is more attractive than Progyny, Inc..

Progyny, Inc. has a beta of 0.932, which suggesting that the stock is 6.785% less volatile than S&P 500. In comparison Clover Health Investments Corp. has a beta of 2.120, suggesting its more volatile than the S&P 500 by 111.968%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clover Health Investments Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny, Inc. pays -- of its earnings as a dividend. Clover Health Investments Corp. pays out -- of its earnings as a dividend.

Progyny, Inc. quarterly revenues are $313.3M, which are smaller than Clover Health Investments Corp. quarterly revenues of $496.7M. Progyny, Inc.'s net income of $13.9M is higher than Clover Health Investments Corp.'s net income of -$24.4M. Notably, Progyny, Inc.'s price-to-earnings ratio is 37.79x while Clover Health Investments Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.68x versus 0.63x for Clover Health Investments Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Centene Corp. has a net margin of 4.43% compared to Progyny, Inc.'s net margin of -13.35%. Progyny, Inc.'s return on equity of 11.79% beat Centene Corp.'s return on equity of -20.3%.

Progyny, Inc. has a consensus price target of $30.91, signalling upside risk potential of 29.49%. On the other hand Centene Corp. has an analysts' consensus of $43.88 which suggests that it could grow by 1.3%. Given that Progyny, Inc. has higher upside potential than Centene Corp., analysts believe Progyny, Inc. is more attractive than Centene Corp..

Progyny, Inc. has a beta of 0.932, which suggesting that the stock is 6.785% less volatile than S&P 500. In comparison Centene Corp. has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.088%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Centene Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny, Inc. pays -- of its earnings as a dividend. Centene Corp. pays out -- of its earnings as a dividend.

Progyny, Inc. quarterly revenues are $313.3M, which are smaller than Centene Corp. quarterly revenues of $49.7B. Progyny, Inc.'s net income of $13.9M is higher than Centene Corp.'s net income of -$6.6B. Notably, Progyny, Inc.'s price-to-earnings ratio is 37.79x while Centene Corp.'s PE ratio is 8.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.68x versus 0.12x for Centene Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare, Inc. has a net margin of 4.43% compared to Progyny, Inc.'s net margin of 0.69%. Progyny, Inc.'s return on equity of 11.79% beat Molina Healthcare, Inc.'s return on equity of 19.74%.

Progyny, Inc. has a consensus price target of $30.91, signalling upside risk potential of 29.49%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $186.69 which suggests that it could grow by 3.95%. Given that Progyny, Inc. has higher upside potential than Molina Healthcare, Inc., analysts believe Progyny, Inc. is more attractive than Molina Healthcare, Inc..

Progyny, Inc. has a beta of 0.932, which suggesting that the stock is 6.785% less volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.491, suggesting its less volatile than the S&P 500 by 50.861%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny, Inc. pays -- of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend.

Progyny, Inc. quarterly revenues are $313.3M, which are smaller than Molina Healthcare, Inc. quarterly revenues of $11.5B. Progyny, Inc.'s net income of $13.9M is lower than Molina Healthcare, Inc.'s net income of $79M. Notably, Progyny, Inc.'s price-to-earnings ratio is 37.79x while Molina Healthcare, Inc.'s PE ratio is 11.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.68x versus 0.22x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health, Inc. has a net margin of 4.43% compared to Progyny, Inc.'s net margin of -4.6%. Progyny, Inc.'s return on equity of 11.79% beat Oscar Health, Inc.'s return on equity of -21.36%.

Progyny, Inc. has a consensus price target of $30.91, signalling upside risk potential of 29.49%. On the other hand Oscar Health, Inc. has an analysts' consensus of $15.78 which suggests that it could grow by 9.95%. Given that Progyny, Inc. has higher upside potential than Oscar Health, Inc., analysts believe Progyny, Inc. is more attractive than Oscar Health, Inc..

Progyny, Inc. has a beta of 0.932, which suggesting that the stock is 6.785% less volatile than S&P 500. In comparison Oscar Health, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Progyny, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny, Inc. pays -- of its earnings as a dividend. Oscar Health, Inc. pays out -- of its earnings as a dividend.

Progyny, Inc. quarterly revenues are $313.3M, which are smaller than Oscar Health, Inc. quarterly revenues of $3B. Progyny, Inc.'s net income of $13.9M is higher than Oscar Health, Inc.'s net income of -$137.5M. Notably, Progyny, Inc.'s price-to-earnings ratio is 37.79x while Oscar Health, Inc.'s PE ratio is 51.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny, Inc. is 1.68x versus 0.34x for Oscar Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.